To better comprehend what dictates the response to these two targeted therapies, we established their mutational profile for key oncogenes and tumor suppressors (Fig S1A), as well as their baseline phosphorylation level for three major kinases p-ERK (T202/Y204, MAPK pathway), p-AKT (S473, PI3K pathway) and p-S6 (S235/S236, mTOR pathway) (Fig S1B, C). This evidence concerns the gene MAPK1 and neoplasm.